Ashley Gallagher, Editor

Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.

Mylo Wells, PharmD, owner of Wells Hometown Drug and Wells Hometown Drug Keosauqua, aims to give back to the community where he grew up.

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Clinical data from phase 1/2 LIBRETTO trial show evidence of meaningful clinical outcomes for patients, including those with difficult-to-treat brain metastases.

Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.

Individuals with immunity obtained through having the disease still experienced expanded T-cell memory and immune activation after being immunized, study results show.

Study results show at a molecular level how fidaxomicin selectively targets these bacteria, while sparing others in the gut microbiome.

Study results show that an individual received little or no relief from doing yoga, eliminating certain foods, practicing medication, or taking prescribed medications.

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

In studies of rats, results show that supplementation preserves skeletal muscle after patients take the chemotherapy medication doxorubicin.

Genome sequencing shows the clonality of outbreak isolates within each of 6 classes, which confirmed that recent transmissions accounted for high carriage.

Phase 3 REST-ON Trial data show that the medication demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared with the placebo.

BioXcel plans to launch Igalmi sublingual film in the United States in the second quarter of 2022.

Drug meets primary endpoint at 50 mg with reduction in low-density lipoprotein levels from the baseline in the ETESIAN phase 2b trial

Regeneron’s supplemental biologics license application for the drug targets patients aged 12 years and older.

Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

The eye drop treats age-related blurry near vision in adults and is FDA-approved for once-daily administration.

Session at the Hematology/Oncology Pharmacy Association Annual Conference 2022 focuses on methods to improve emotional exhaustion among pharmacists and other health care providers.

With risk stratification, up to 60% of individuals with chronic myeloid leukemia who are low-risk sustain treatment-free remission.

These include progression-free survival, time to treatment failure, and time to tumor progression, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.

Analysis from the American Society of Health-System Pharmacists indicates turnover rates of at least 21% in 2021.

Patient treatment improves and medication prices decline as a result, a new analysis indicates.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.

Heat waves, which are on the rise, appear to pose particular cardiovascular risk for Black populations and men, new study results show.

Most other compounds undergoing clinical trials target testosterone, which can lead to depression, higher low-density lipoprotein cholesterol levels, and weight gains.